Floatz logo

gh55

Advanced Solid Tumor Cancer

Suzhou Genhouse Bio Co., Ltd.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Advanced Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Shr-A1811
Sheng Zhang
Phase 2CCC
lm-24c5
LaNova Medicines Limited
Phase 2CCC
Capecitabine
National University Hospital, Singapore
Phase 1/2CCC
bnt3214
BioNTech SE
Phase 1/2CC
Tislelizumab
National University Hospital, Singapore
Phase 1/2CC

View all 19 →

Same molecule, other indications

gh55 is also rated in:

Lymphoblastic Leukemia in ChildrenDormant
CCC
Indicative ·
48 / 100
View asset →
Lymphoblastic LeukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
Lymphoblastic Leukemia, Acute AdultDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →